
Daunorubicin injection
Form: Intravenous (IV) injection:
Strength: 20 mg/mL
Reference Brands: Cerubidine(US)
Category: Blood Disorder
Daunorubicin injection, marketed as Cerubidine, is approved in the US by the FDA and in the EU via EMA for treating leukemia, primarily acute myeloid leukemia. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, submission involves detailed review by the FDA, whereas in the EU, the EMA ensures compliance with regional quality standards. For expert guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring adherence to regional regulations is essential for the safe, effective, and timely approval of daunorubicin injection worldwide, supporting optimal patient treatment outcomes.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Strength: 500 units, 1000 units, and 2500 units
Form: Lyophilized Powder (Reconstituted for IV infusion)
Reference Brands: FEIBA(US)
View Details Get EnquiryProthrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get Enquiry